Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up Study After Phase I Study of MTC001 (VCF1) for Chronic Ischemic Heart Failure
jRCT1030230216Suspended
- Sponsor
- Machino Takeshi
- Start
- Jul 2023
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of MTC001 in ischaemic cardiomyopathy (ICM), sponsored by Machino Takeshi. Primary endpoint: Occurrence of major cardiovascular events. Started Jul 2023; status: suspended.
02
Drugs
MTC001
03
Conditions
ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on jRCT1030230216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230216.